Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

More Pressure On Pradaxa? US Payers May Narrow Coverage Of NOACs

US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with two of the leading drugs in the field, rather than all three.

Research & Development Reimbursement

Abuse-Deterrent Opioids: ICER Value Analysis Could Reinforce Coverage Restrictions

Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.

Policy Reimbursement

Putting The 'Big' Back In PhRMA: New Membership Criteria Pares Ranks

PhRMA eliminates 42% of members in conjunction with new membership eligibility criteria stipulating minimum R&D investment levels.

Pricing Debate Policy

Tymlos, Evenity Pricing: Should Generic Zoledronic Be Reference Point?

ICER draft report concluding data are insufficient to distinguish the effectiveness of anabolic treatments for osteoporosis from generic zoledronic acid raises questions about price premiums for the newer treatments.

Reimbursement Pricing Strategies

US Branded Drug Invoice Price Increases Moderate In 2016

Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.

Pricing Debate Pricing Strategies

US Branded Drug Invoice Price Increases Moderate In 2016

Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.

Pricing Debate Pricing Strategies
See All
Advertisement
UsernamePublicRestriction

Register